Prepared on behalf of the PES Drugs and Therapeutics Committee by Kristal Matlock, MD, Dania Al-Hamad, MD, Vandana Raman, MD and Amit Lahoti, MD FDA approval…
Read MoreBrief Therapeutic Update from PES Drugs and Therapeutics Committee (THYQUIDITYTM) THYQUIDITYTM is a liquid levothyroxine preparation that is FDA approved for (i) treatment of congenital or…
Read MoreNot a member yet? Join the largest Pediatric Endocrine community and unlock a host of tools, resources, and enhance your network! Click here to learn more.
Approval of generic glucagon for management of hypoglycemia Prepared by: Kristal Matlock, Preneet Cheema Brar, Molly Regelmann UpToDate as of: 1/20/2021 On December 28, 2020, the…
Read MoreSetmelanotide Prepared by: Anshu Gupta, MD, MS and Brenda Kohn, MD Up-to-date as of December 14, 2020 On November 27, 2020, setmelanotide (IMCIVREE™; Rhythm Pharmaceuticals, Inc.),…
Read MoreSaxenda (Liraglutide) Approved for Adolescent Obesity Prepared by: Laura Page, MD and Shilpa Mehta, MD Up to date as of December 10, 2020 On December 4,…
Read MoreHydrocortisone Granules (Alkindi Sprinkle) Prepared by: Takara Stanley, Seth Marks and Kyriakie Sarafoglou Up to date as of: November 4, 2020 On September 29, 2020, the…
Read MorePrepared by: Vandana Raman, Shilpa Mehta, and Amit Lahoti. Last Updated on: 8/11/20 Liraglutide is a long-acting analog of human glucagon-like peptide (GLP)-1. It was approved…
Read MorePrepared by Bhuvana Sunil, MD and Ambika Ashraf, MD Burosumab twza (Crysvita – Ultragenyx pharmaceuticals) is an injectable recombinant IgG1 human monoclonal antibody preparation neutralizing fibroblast…
Read MorePrepared by Christine Yu and Amit Lahoti Semglee™ is a new biosimilar insulin with an identical amino-acid sequence to insulin glargine. Semglee™, co-developed by Mylan Inc.…
Read More